Vantage logo

Illumina bets on Pacific, not nanopores

Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.